Ran Reshef, MD
Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.
The Reshef lab is focused on two primary areas:
1. Investigating lymphocyte trafficking mechanisms that affect anti-tumor and anti-host responses in cancer immunotherapy. The lab pioneered the use of lymphocyte trafficking antagonists as a way to prevent graft-versus-host disease after allogeneic stem-cell transplantation, a strategy that is currently examined in a national multi-center trial.
2. Identifying genomic and phenotypic predictors for the outcomes of stem-cell transplantation and other forms of cancer immunotherapy. The lab uses a diverse toolset that includes genomic, immunophenotypic and computational biology methods to identify novel factors and biomarkers that predict outcomes such as cancer recurrence and graft-versus-host disease. The discovery of these predictors is then used to develop personalized transplant approaches, optimize donor selection and understand immunologic mechanisms that are critical to the success of stem-cell transplantation.
Dr. Reshef’s research is funded by the National Cancer Institute, American Society of Clinical Oncology, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and American Society of Hematology.
Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). “Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease.” N Engl J Med 367:135-145
Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). “High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning” J Clin Oncol 33:2392-2398.
Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916